Navigation Links
New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
Date:10/17/2008

oup, reports of nausea fell to 13% after 8-10 weeks of treatment and remained above 10% for more than 20 weeks.

Other common gastrointestinal-related adverse events with liraglutide were diarrhea, vomiting and dyspepsia.

Patients on both treatments lost weight during the study. Weight reduction in patients on liraglutide was also consistently seen in the LEAD(TM) 3a studies.

Key LEAD(TM) 6 data:

Liraglutide 1.8 mg QD + Exenatide 10 micrograms, BID +

metformin and/or SU metformin and/or SU

N=233 N=231

Diabetes duration,

years at baseline 8.5 7.9

BMI, kg/m(2) at

baseline 32.9 32.9

HbA1c, % at baseline 8.2 8.1

Change in HbA1c % (SE)

from baseline -1.12* (0.08) -0.79 (0.08)

% HbA1c <7.0% 54* 43

% HbA1c less than or

equal to 6.5% 35* 21

Weight change, kg from

baseline -3.24 -2.87

% Change in HOMA-B

from baseline 32.1* 2.7

Change FPG (fasting plasma glucose)

mmol/L from baseline -1.61* -0.60

Minor hypoglycemic

events/subject/year 1.9* 2.6

*P<0.05

About liraglutide

Once-daily liraglutide is the first human glucagon-like peptide-1 (GLP-1) analog developed for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin and inhibiting the release of glucagon from the liver afte
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Inc. Magazine ... States, ranking iLab Solutions as number 1,361 in growth for the three years through ... the top 0.1% fastest-growing privately held organizations in the country. , “We are ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet ... a second US laboratory is to open in Manhattan, Kansas in early October, ... and long-term growth of research and development through collaboration with researchers from Kansas ...
(Date:8/26/2015)... 26, 2015  The Diabetes Research Institute (DRI), ... Miami Miller School of Medicine, announced today that ... test for the first time a novel transplant ... FDA approved Phase I/II study builds upon decades ... an important first step toward the development of ...
(Date:8/26/2015)... Aug. 26, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has been informed ... entity wholly owned by Mr. Yuen Kam, chairman of ... the outstanding shares (the "Shares") of  Excellent China Healthcare ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... Recurring Disposables, Services and Accessories Revenue ... Irrigated Catheter Launch Provided, ST. LOUIS, March 3 ... the fourth quarter and full year,ended December 31, 2007., ... to $39.3 million,compared with $27.2 million in 2006. Sales ...
... Feb. 29 For the first time,researchers at ... spheres whose halves are physically or chemically,different -- ... when an alternating electrical field is applied to ... research, published in the Feb. 8, 2008, edition,of ...
... Feb. 29 Kendle (Nasdaq: KNDL ... today,announced that Vice President and Chief Marketing ... Annual Raymond James,Institutional Investors Conference. The conference ... Cypress in Orlando, March 2-5, 2008. Kendle,s,presentation ...
Cached Biology Technology:Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 3Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 4Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 5Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 6Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 7Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 8Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 9Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 10'Two-Faced' Particles Act Like Tiny Submarines 2'Two-Faced' Particles Act Like Tiny Submarines 3Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference 2
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:7/31/2015)... Kina, 31. juli 2015 Den 10. internationale ... af BGI fra den 22. - 25. oktober i ... fejrer sin 10-års fødselsdag i år. Siden starten i ... årlige møder på ,omik,-feltet, og er en af de ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... known that racing cars and bicyclists can reduce air ... from New York University and Cornell University have found ... flags. Their study, published in the most recent issue ... that in a series of flags, the leading flag ...
... increasing popularity of reduced tillage on crops has not ... but it has also been associated with increasing organic ... peanut crops, however, reduced tillage has not gained a ... inconsistent yields have not encouraged farmers to make a ...
... With childhood obesity increasing, school administrators and public health ... schools. In a study published in the November/December 2008 ... Behavior , researchers found that reduction or elimination of ... consumption by adolescents. Working with four schools ...
Cached Biology News:Lead-flapping objects experience less wind resistance than their trailing counterparts 2Tillage, rotation impacts peanut crops 2
... LiCl precipitation offers major advantages over other ... precipitate DNA, protein or carbohydrates. It is the ... or cDNA synthesis from RNA preparations. Note, LiCl ... total RNA isolations. If the RNA is to ...
...
...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
Biology Products: